SI1851241T1 - Močno potentni polni in delni agonisti in antagonisti receptorja nociceptina/orfanina fq - Google Patents

Močno potentni polni in delni agonisti in antagonisti receptorja nociceptina/orfanina fq

Info

Publication number
SI1851241T1
SI1851241T1 SI200631947T SI200631947T SI1851241T1 SI 1851241 T1 SI1851241 T1 SI 1851241T1 SI 200631947 T SI200631947 T SI 200631947T SI 200631947 T SI200631947 T SI 200631947T SI 1851241 T1 SI1851241 T1 SI 1851241T1
Authority
SI
Slovenia
Prior art keywords
orphanin
nociceptin
antagonists
receptor
partial agonists
Prior art date
Application number
SI200631947T
Other languages
English (en)
Inventor
Remo Guerrini
Severo Salvadori
Girolamo Calo'
Domenico Regoli
Original Assignee
Ufpeptides S.R.I.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ufpeptides S.R.I. filed Critical Ufpeptides S.R.I.
Publication of SI1851241T1 publication Critical patent/SI1851241T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
SI200631947T 2005-02-15 2006-02-15 Močno potentni polni in delni agonisti in antagonisti receptorja nociceptina/orfanina fq SI1851241T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT000003A ITFE20050003A1 (it) 2005-02-15 2005-02-15 Agonisti pieni e parziali ed antagonisti del recettore per nocicettina/orfanina fq ad elevata potenza.
EP06708285.9A EP1851241B1 (en) 2005-02-15 2006-02-15 Highly potent full and partial agonists and antagonists of the nociceptin/orphanin fq receptor
PCT/EP2006/050958 WO2006087340A2 (en) 2005-02-15 2006-02-15 Highly potent full and partial agonists and antagonists of the nociceptin/orphanin fq receptor

Publications (1)

Publication Number Publication Date
SI1851241T1 true SI1851241T1 (sl) 2015-08-31

Family

ID=36685750

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200631947T SI1851241T1 (sl) 2005-02-15 2006-02-15 Močno potentni polni in delni agonisti in antagonisti receptorja nociceptina/orfanina fq

Country Status (29)

Country Link
US (1) US8227414B2 (sl)
EP (1) EP1851241B1 (sl)
JP (1) JP5281292B2 (sl)
KR (1) KR101294895B1 (sl)
CN (2) CN101128482A (sl)
AU (1) AU2006215639B2 (sl)
BR (1) BRPI0606998B8 (sl)
CA (1) CA2598121C (sl)
CR (1) CR9379A (sl)
CU (1) CU23823A3 (sl)
CY (1) CY1116456T1 (sl)
DK (1) DK1851241T3 (sl)
EA (1) EA011325B1 (sl)
ES (1) ES2541308T3 (sl)
HR (1) HRP20150731T1 (sl)
HU (1) HUE025000T2 (sl)
IL (1) IL185235A (sl)
IT (1) ITFE20050003A1 (sl)
MA (1) MA29288B1 (sl)
MX (1) MX2007009523A (sl)
NI (1) NI200700205A (sl)
NO (1) NO341856B1 (sl)
PL (1) PL1851241T3 (sl)
PT (1) PT1851241E (sl)
RS (1) RS54095B1 (sl)
SI (1) SI1851241T1 (sl)
UA (1) UA91844C2 (sl)
WO (1) WO2006087340A2 (sl)
ZA (1) ZA200707714B (sl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITNA20090026A1 (it) * 2009-05-14 2010-11-15 Agostino Bruno D Agonisti del recettore nop e loro usi terapeutici
CN112730849B (zh) * 2021-01-14 2023-03-10 山西医科大学第二医院 内源性孤啡肽作为糖尿病合并无症状性心肌缺血的血清生物标志物的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1499888T1 (sl) 2002-04-29 2010-11-30 Euro Celtique Sa Konformacijsko omejeni peptidi ki vežejo ORL receptor
ITMI20022022A1 (it) * 2002-09-24 2004-03-25 Girolamo Calo' Analoghi di nocicettina.
ITMI20031349A1 (it) * 2003-07-01 2005-01-02 Ufpeptides S R L Antagonisti del recettore nop e loro usi terapeutici.
CN1634980A (zh) * 2004-10-10 2005-07-06 兰州大学 孤啡肽的类似物

Also Published As

Publication number Publication date
EA011325B1 (ru) 2009-02-27
EP1851241B1 (en) 2015-04-08
HRP20150731T1 (hr) 2015-08-14
EA200701732A1 (ru) 2008-02-28
NO20074702L (no) 2007-10-29
KR101294895B1 (ko) 2013-08-08
CN101128482A (zh) 2008-02-20
NO341856B1 (no) 2018-02-12
BRPI0606998B8 (pt) 2021-05-25
IL185235A (en) 2014-08-31
JP5281292B2 (ja) 2013-09-04
EP1851241A2 (en) 2007-11-07
CA2598121C (en) 2014-11-25
ES2541308T3 (es) 2015-07-17
WO2006087340A2 (en) 2006-08-24
MX2007009523A (es) 2007-09-07
CY1116456T1 (el) 2017-03-15
WO2006087340A3 (en) 2006-10-26
NI200700205A (es) 2008-06-17
RS54095B1 (en) 2015-10-30
US20100273710A1 (en) 2010-10-28
PT1851241E (pt) 2015-08-28
AU2006215639B2 (en) 2011-05-26
CR9379A (es) 2008-04-25
AU2006215639A1 (en) 2006-08-24
JP2008530058A (ja) 2008-08-07
BRPI0606998A2 (pt) 2014-01-21
US8227414B2 (en) 2012-07-24
ITFE20050003A1 (it) 2006-08-16
BRPI0606998B1 (pt) 2018-04-10
CU23823A3 (es) 2012-06-21
IL185235A0 (en) 2008-02-09
MA29288B1 (fr) 2008-02-01
WO2006087340A8 (en) 2007-06-21
CA2598121A1 (en) 2006-08-24
PL1851241T3 (pl) 2015-09-30
KR20070119614A (ko) 2007-12-20
HUE025000T2 (en) 2016-01-28
UA91844C2 (ru) 2010-09-10
CN104689293A (zh) 2015-06-10
ZA200707714B (en) 2008-06-25
DK1851241T3 (en) 2015-06-29

Similar Documents

Publication Publication Date Title
IL190336A0 (en) Imidazopyridine derivatives as a2b adenosine receptor antagonists
GB0611154D0 (en) Novel receptor antagonists and their methods of use
HK1136302A1 (en) Progesterone receptor antagonists
EP1871752A4 (en) ANTAGONISTS OF THE AMIDOPROPOXYPHENYLOREXIN RECEPTOR
AP2008004441A0 (en) Piperdin-4-ylpyrazin-2-ylamine derivatives as fastdissociating dopamine 2 receptor antagonists
IL189453A0 (en) Carboxamide derivatives as muscarinic receptor antagonists
IL199015A0 (en) Quinuclidinol derivatives as muscarinic receptor antagonists
IL187972A0 (en) Piperazine-pipridine antagonists and agonists of the 5-ht1a receptor
IL179462A0 (en) Use of the receptor gpr86
HUP0600858A2 (en) Piperizinyilpiperidine derivatives as chemokine receptor antagonists
EP2032797A4 (en) ADENOSINE A2B RECEPTOR ANTAGONISTS
ZA200903574B (en) 2-Phenyl-6-Aminocarbonyl-Pyrimidine derivatives and their use as P2Y12 Receptor antagonists
IL198542A0 (en) 2-aminoquinolines as 5-ht(5a)receptor antagonists
IL205949A0 (en) 3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists
HK1137434A1 (en) Piperidinylamino-pyridazines and their use as fast dissociating dopamine 2 receptor antagonists
IL200380A0 (en) Mineralcorticoid receptor antagonists for the treatment of endometriosis
HK1102303A1 (en) Synthesis of ccr5 receptor antagonists ccr5
ZA200707714B (en) Highly potent full and partial agonists and antagonists of the nociceptin/orphanin FQ receptor
IL185640A0 (en) Use of 2-anilino-3 ,4-dihydro-quinazolines as 5ht5a receptor antagonists
AP2008004537A0 (en) Muscarinic receptor antagonists
ZA200806223B (en) Muscarinic receptor antagonists
ZA200608369B (en) Piperazinylpiperidine derivatives as chemokine receptor antagonists
GB0611155D0 (en) Novel receptor antagonists and their methods of use
GB0611157D0 (en) Novel receptor antagonists and their methods of use
GB0604234D0 (en) Novel receptor antagonists and their methods of use